Novel Long-Acting Buprenorphine Medications for Opioid Dependence:
                    Current Update

Michael Soyka

doi:10.1055/a-1298-4508

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2021; 54(01): 18-22
DOI: 10.1055/a-1298-4508

Review

Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update

Michael Soyka

Abstract

Opioid maintenance treatment with oral methadone or sublingual buprenorphine is the first-line treatment in opioid dependence. Three novel long-acting buprenorphine formulations have been approved or will be available soon: for subcutaneous weekly and monthly application, the depot formulations CAM 2038 (Buvidal^®), the monthly depot formulation RBP-6000 (Sublocade™), and a 6-month buprenorphine implant (Probuphine™). Clinical data available so far on the efficacy of these 3 medications are given, and possible clinical implications are discussed.

Key words

opioid dependence - maintainance treatment - buprenorphine - depot - implant

Full Text

References

References
1 Degenhardt L, Charlson F, Mathers B. et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction 2014; 109: 1320-1333
2 Schuckit MA. Treatment of opioid-use disorders. N Engl J Med 2016; 375: 1596-1597
3 Atzendorf J, Rauschert L, Seitz NN. et al. Gebrauch von Alkohol, Tabak, illegalen Drogen und Medikamenten. Dtsch Ärzteblatt 2019; 116: 577-584
4 Center for Behavioral Health Statistics and Quality (CBHSQ). National survey on drug use and health: Detailed tables. Substance Abuse and Mental Health Services Administrations, Rockville, MD 2016
5 Bell J, Strang J. Medication treatment of opioid use disorder. Biol Psychiatry 2020; 87: 82-88
6 McLellan AT, McKay JR, Forman R. et al. Reconsidering the evaluation of addiction treatment: from retrospective follow-up to concurrent recovery monitoring. Addiction 2005; 100: 447-458
7 Russolillo A, Moniruzzaman A, McCandless LC. et al. Associations between methadone maintenance treatment and crime: A 17-year longitudinal cohort study of Canadian provincial offenders. Addiction 2018; 113: 656-667
8 Dennis ML, Scott CK, Funk R. et al. The duration and correlates of addiction and treatment careers. J Subst Abuse Treat 2005; 28: 51-62
9 Gossop M, Marsden J, Stewart D. et al. Outcomes after methadone maintenance and methadone reduction treatments: Two-year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend 2001; 62: 255-264
10 Bell J. Pharmacological maintenance treatments of opiate addiction. Br J Clin Pharmacol 2014; 77: 253-263
11 Amato L, Minozzi S, Davoli M. et al. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2011; 10: CD004147
12 Mattick RP, Breen C, Kimber J. et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; CD002207
13 Soyka M, Strehle J, Rehm J. et al. Six-year outcome of opioid maintenance treatment in heroin-dependent patients: Results from a naturalistic study in a nationally representative sample. Eur Addict Res 2017; 23: 97-105
14 Walter M, Soyka M. Opioide. In: Soyka M, Batra A, Heinz A, Moggi F, Walter M. Suchtmedizin. München: Elsevier; 2019: 177-202
15 Volkow ND, Frieden TR, Hyde PS. et al. Medication-assisted therapies: Tackling the opioid-overdose epidemic. N Engl J Med 2014; 370: 2063-2066
16 Rehm J, Gschwend P, Steffen T. et al. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study. Lancet 2001; 358: 1417-1423
17 Strang J, Groshkova T. Uchtenhagen. et al. Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine prescribing as treatment for refractory heroin addiction. Br J Psychiatry 2015; 207: 5-14
18 Teesson M, Mills K, Ross J. et al. The impact of treatment on 3 years’ outcome for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Addiction 2007; 103: 80-88
19 Kimber J, Larney S, Hickman M. et al. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: A retrospective cohort study. Lancet Psychiat 2015; 2: 901-908
20 Bundesärztekammer. Richtlinie der Bundesärztekammer zur Durchführung der substitutionsgestützten Behandlung Opioidabhängiger 2017; Im Internet: www.bundesaerztekammer.de/fileadmin/user_upload/ downloads/pdf-Ordner/RL/Substitution.pdf; Stand: 18.11.2019
21 Bell J, Burrell T, Indig D. et al. Cycling in and out of treatment; participation in methadone treatment in NSW, 1990–2002. Drug Alcohol Depend 2006; 81: 55-61
22 Zhang L, Zou X, Zhang D. et al. Investigation of repeat client drop-out and re-enrolment cycles in fourteen methadone maintenance treatment clinics in Guangdong, China. PLoS One 2015; 10: e0139942
23 Bell J. The global diversion of pharmaceutical drugs: opiate treatment and the diversion of pharmaceutical opiates: a clinician’s perspective. Addiction 2010; 105: 1531-1537
24 Timko C, Schultz NR, Cucciare MA. et al. Retention in medication-assisted treatment for opiate dependence: A systematic review. J Addict Dis 2016; 35: 22-35
25 Fareed A, Vayalapalli S, Casarella J. et al. Effect of buprenorphine dose on treatment outcome. J Addict Dis 2012; 31: 8-18
26 Greenwald MK, Comer SD, Fiellin DA. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: Implications for clinical use and policy. Drug Alcohol Depend 2014; 144: 1-11
27 Greenwald MK, Johanson CE, Moody DE. et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacol 2003; 28: 2000-2009
28 Kuhlman JJ, Levine B, Johnson RE. et al. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 1998; 93: 549-559
29 Hser YI, Evans E, Huang D. et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction 2016; 111: 695-705
30 Hser YI, Saxon AJ, Huang D. et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2014; 109: 8-18
31 Bell J, Butler B, Lawrance A. et al. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009; 104: 73-77
32 Bell J, Trinh L, Butler B. et al. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009; 104: 1193-1200
33 Deamer RL, Wilson DR, Clark DS. et al. Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM). J Addict Dis 2001; 20: 7-14
34 European Agency for the Evaluation of Medical Products. EMEA public statement to suspend the marketing authorization for Orlaam (levoacetylmethadol) in the European Union. 2001; EMEA/8776/01
35 Wieneke H, Conrads H, Wolstein J. et al. Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation-results from a controlled clinical trial. Eur J Med Res 2009; 14: 7-12
36 Ling W, Shoptaw S. Goodman-Meza. Depot buprenorphine in the management of opioid use disorder. From development to implementation. Subst Abuse Rehabil 2019; 10: 69-78
37 Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med 2019; 13: 93-193
38 Walsh SL, Comer SD, Lofwall MR. et al. Effect of buprenorphine weekly depot (CAM 2038) and hydromorphone blockade in individuals with opioid use disorder: a randomised clinical trial. JAMA Psychiatry 2017; 74: 894-902
39 Albayaty M, Linden M, Olsson H. et al. Pharmacokinetic evaluation of one-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM 2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: An open-label phase 1 study. Adv Ther 2017; 34: 560-575
40 Haasen C, Linden M, Tiberg F. Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid disorder. J Subst Abuse Treat 2017; 78: 22-29
41 Lofwall MR, Walsh SL, Nunes EV. et al. Weekly and monthly subcutaneous buprenorhpine depot formulations vs daily sublingual burpenorphine with naloxone for treatment of opioid use disorder: a randomized clinical Trial. JAMA Intern Med 2018; 178: 764-773
42 Frost M, Bailey GL, Lintzeris L. et al. Longtime safety of weekly and monthly subcutaneous Buprenorphindepot (CAM 2038) in the treatment of adult out-patients with opiod use disorders. Addiction 2019; 114: 1416-1426
43 Laffont CM, Gomeni R, Heidbreder C. et al. Population pharmacokinetic modeling after repeated administrations of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid use disorder. J Clin Pharmacol 2016; 56: 806-815
44 Nasser AF, Heidbreder C, Gomeni R. et al. A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. Clin Pharmacokinet 2014; 53: 813-824
45 Haight BR, Learned SM, Laffont CM. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2019; 393: 778-790
46 Ling W, Nadipelli VR, Solem CT. et al. Patient-centered outcomes in participants of a buprenorphine monthly depot (bup-xr) double-blind, placebo-controlled, multicenter, phase study. J Addict Med 2019; 13: 442-449
47 Barnwal P, Das S, Mondal S. et al. Probuphine^® (buprenorphine implant): a promising candidate in opioid dependence. Ther Adv Psychopharmacol 2017; 7: 119-134
48 Itzoe M, Guarnieri M. New developments in managing opioid addiction: impact of a subdermal buprenorphine implant. Drug Des Devel Ther 2017; 11: 1429-1437 doi: 10.2147/DDDT.S109331
49 White J, Bell J, Saunders JB. et al. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend 2009; 103: 37-43.
50 Ling W, Casadonte P, Bigelow G. et al. Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial. JAMA 2010; 304: 1576-1583
51 Rosenthal RN, Ling W, Casadonte P. et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction 2013; 108: 2141-2149
52 Rosenthal RN, Lofwall MR, Kim S. et al. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: A randomized clinical trial. JAMA 2016; 316: 282-290
53 Pendergrass SA, Crist RC, Jones LK. et al. The importance of buprenorphine research in the opioid crisis. Mol Psychiatry 2019; 24: 626-632
54 Kelty E, Cumming C, Troeung L. et al. Buprenorphine alone or with naloxone: Which is safer?. J Psychopharmacol 2018; 32: 344-352
55 Allikmets S, Vink JP. Clinical applications of burprenorphine depot injection for opioid use disorder. Addiction 2020; 115 : doi:10.1111/add.14818
56 Kenney SR, Anderson BJ, Bailey GL. et al. Buprenorphine treatment formulations: Preferences among persons in opioid withdrawal management. J Subst Abuse Treat 2018; 94: 55-59.
57 Tompkins CNE, Neale J, Strang J. Opioid users willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder. J Subst Abuse Treatment 2019; 104: 64-71
58 Neale J, Tompkins CNE, Strang J. Prolonged-release opioid agonist therapy: qualitative study exploring patients views of 1-week. 1-month and 6-month buprenorphine formulations. Harm Reduct J 2019; 16: 25 doi: 10.1186/s12954-019-0296-4
59 Gilman M, Li L, Hudson K. et al. Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine. Patient Prefer Adherence 2018; 12: 2123-2129
60 Ling W, Shoptaw S, Goodman-Meza D. Depot buprenorphine injection in the management of opioid use disorder: from development to implementation. Subst Abuse Rehabil 2019; 10: 69-78
61 Soyka M. Covid-19 and substitution. Suchtmed 2020; 22: 119-121
62 Vorspan F, Hjelström P, Simon N. et al. What place for prolonged-release buprenorphine depot-formulation buvidal in the treatment arsenal if opioid dependence? Insights from the French experience on buprenorphine. Expert Opin Drug Deliv 2019; 16: 907-914
63 Larance B, Degenhardt L, Grebely J. et al. Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. Addiction 2019; 115: 1295-1305
64 Shover CL, Humphreys K. Predictors of availability of long-acting medication for opioid use disorder. Drug Alcohol Depend 2019; doi.
65 Hjelström P, Nordbeck EB, Tiberg F. Optimal dose of buprenorphine in opioid use disorder treatment: A review of pharmacodynamic and efficacy data. Drug Dev Ind Pharm 2020; doi.
66 McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. Am J Addict 2010; 19: 4-16
67 Liu T, Gobburu VS. A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions of buprenorphine after subcutaneous administration of CAM2038 with perpetrators of CYP3A4. J Pharm Sci 2018; 107: 942-948